Latest News and Press Releases

Chicago, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Epigenetics market in terms of revenue was estimated to be worth $1.8 billion in 2023 and is poised to reach $4.3 billion by 2028, growing at a CAGR of...

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- K36 Therapeutics (“K36”) has been selected as “Overall BioPharma Startup of the Year” in the third annual BioTech Breakthrough Awards Program...

 - Key Catalysts ahead with Multiple Value Generating Readouts-- Expects to Release Phase 1/2 Data with Oral Fadraciclib -- Signals of Single-agent Efficacy with Oral Plogosertib -- Management to Host...

Chicago, July 03, 2023 (GLOBE NEWSWIRE) -- In the near future, the epigenetics industry is poised for remarkable advancements and transformative impact in various fields. Epigenetics, the study of...

Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass...

SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...

High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favourable research funding scenario are key factors contributing to high CAGR...

SOUTH SAN FRANCISCO, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, today announced a new bimodal single‑cell application...

CAMBRIDGE, MA--(Marketwired - May 23, 2017) - Elsevier, the information analytics company specializing in science and health, today announced a new book series, Advances in Stem Cells and their...